168 related articles for article (PubMed ID: 22524974)
1. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Olnes MJ; Shenoy A; Weinstein B; Pfannes L; Loeliger K; Tucker Z; Tian X; Kwak M; Wilhelm F; Yong AS; Maric I; Maniar M; Scheinberg P; Groopman J; Young NS; Sloand EM
Leuk Res; 2012 Aug; 36(8):982-9. PubMed ID: 22524974
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
3. Targeting cyclin D1 for high risk myelodysplastic syndromes.
Mundle SD
Leuk Res; 2012 Aug; 36(8):964-5. PubMed ID: 22607960
[No Abstract] [Full Text] [Related]
4. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
5. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Seetharam M; Fan AC; Tran M; Xu L; Renschler JP; Felsher DW; Sridhar K; Wilhelm F; Greenberg PL
Leuk Res; 2012 Jan; 36(1):98-103. PubMed ID: 21924492
[TBL] [Abstract][Full Text] [Related]
6. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
Bernell P; Jacobsson B; Nordgren A; Hast R
Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
[TBL] [Abstract][Full Text] [Related]
8. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.
Saberwal G; Broderick E; Janssen I; Shetty V; Alvi S; Lisak L; Venugopal P; Raza A; Mundle SD
J Hematother Stem Cell Res; 2003 Aug; 12(4):443-50. PubMed ID: 12965081
[TBL] [Abstract][Full Text] [Related]
9. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.
Chen G; Zeng W; Miyazato A; Billings E; Maciejewski JP; Kajigaya S; Sloand EM; Young NS
Blood; 2004 Dec; 104(13):4210-8. PubMed ID: 15315976
[TBL] [Abstract][Full Text] [Related]
10. New therapeutics for myelodysplastic syndromes.
List AF
Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol Suppresses Growth and Migration of Myelodysplastic Cells by Inhibiting the Expression of Elevated Cyclin D1 (CCND1).
Zhou W; Xu S; Ying Y; Zhou R; Chen X
DNA Cell Biol; 2017 Nov; 36(11):966-975. PubMed ID: 29035583
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
13. Trisomy of chromosome 8 in myelodysplastic syndrome. Significance of the fluctuating trisomy 8 population.
Iwabuchi A; Ohyashiki K; Ohyashiki JH; Sasao I; Murakami T; Kodama A; Toyama K
Cancer Genet Cytogenet; 1992 Aug; 62(1):70-4. PubMed ID: 1521238
[TBL] [Abstract][Full Text] [Related]
14. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
15. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
[TBL] [Abstract][Full Text] [Related]
16. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.
Sloand EM; Pfannes L; Chen G; Shah S; Solomou EE; Barrett J; Young NS
Blood; 2007 Mar; 109(6):2399-405. PubMed ID: 17090657
[TBL] [Abstract][Full Text] [Related]
17. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
18. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
[TBL] [Abstract][Full Text] [Related]
19. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
Sloand EM; Mainwaring L; Fuhrer M; Ramkissoon S; Risitano AM; Keyvanafar K; Lu J; Basu A; Barrett AJ; Young NS
Blood; 2005 Aug; 106(3):841-51. PubMed ID: 15827127
[TBL] [Abstract][Full Text] [Related]
20. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
